← The Wire
RARENasdaq
Ultragenyx Pharmaceutical Inc.
Pharmaceutical Preparations · DE · CIK 1515673
Develops and commercializes therapies for rare and serious diseases
red 8-K · 90d
$2.40B
Market cap
$30.68
Last close
-0.3%
1D
+5.7%
5D
4.0M
Volume
Price · last 39 sessions+23.7%
May 4L $21.59 · H $30.77Jun 29
286
Total filings
May 18, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 18, 202610-Q10-QMay 6, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 30, 20268-KCompany UpdateApr 2, 20268-KCompany UpdateMar 30, 2026DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSMar 27, 2026DEF 14ADEFINITIVE PROXY STATEMENTMar 27, 20268-KCompany UpdateMar 12, 20268-KCompany UpdateFeb 23, 202610-K10-KFeb 18, 20268-KResults of Operations · Exit / Disposal CostsFeb 12, 20268-KCompany UpdateFeb 3, 20268-KCompany UpdateJan 30, 20268-KResults of OperationsJan 12, 20268-KCompany UpdateDec 30, 20258-KCompany UpdateDec 29, 202510-Q10-QNov 5, 20258-KMaterial Agreement · Results of OperationsNov 4, 20258-KCompany UpdateOct 30, 20258-KCompany UpdateSep 8, 20258-KCompany UpdateAug 18, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 5, 20258-KCompany UpdateJul 31, 20258-KCompany UpdateJul 11, 20258-KCompany UpdateJul 9, 20258-KCompany UpdateJun 27, 20258-KExecutive Change · Shareholder VoteMay 19, 202510-Q10-QMay 7, 20258-KResults of OperationsMay 6, 2025DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSMar 28, 2025DEF 14ADEFINITIVE PROXY STATEMENTMar 28, 202510-K10-KFeb 19, 20258-KResults of OperationsFeb 13, 20258-KResults of OperationsJan 13, 20258-KCompany UpdateDec 19, 20248-KCompany UpdateDec 19, 20248-KCompany UpdateNov 12, 202410-Q10-QNov 6, 20248-KResults of OperationsNov 5, 20248-KCompany UpdateOct 7, 20248-KCompany UpdateOct 3, 202410-Q10-QAug 2, 20248-KResults of OperationsAug 1, 20248-KCompany UpdateJul 17, 20248-KExecutive Change · Shareholder VoteJun 21, 20248-KMaterial AgreementJun 17, 2024424B5424B5Jun 14, 2024424B5424B5Jun 12, 20248-KCompany UpdateJun 12, 20248-KCompany UpdateJun 12, 20248-KCompany UpdateMay 30, 202410-Q10-QMay 3, 20248-KResults of OperationsMay 2, 2024DEFA14AULTRAGENYX PHARMACEUTICAL INC. - DEFA14AApr 26, 2024DEF 14AULTRAGENYX PHARMACEUTICAL INC. - DEF 14AApr 26, 20248-KCompany UpdateApr 15, 202410-K10-KFeb 21, 20248-KResults of OperationsFeb 15, 2024SC 13GSC 13GFeb 13, 20248-KResults of OperationsJan 8, 20248-KBylaw AmendmentDec 21, 202310-Q10-QNov 3, 20238-KResults of OperationsNov 2, 20238-KMaterial AgreementOct 23, 2023424B5424B5Oct 20, 2023424B5424B5Oct 17, 20238-KResults of Operations · Reg FD DisclosureOct 16, 20238-KExecutive ChangeSep 8, 202310-Q10-QAug 4, 20238-KResults of OperationsAug 3, 20238-KExecutive Change · Reg FD DisclosureJul 12, 20238-KReg FD Disclosure · Company UpdateJul 6, 20238-KExecutive Change · Shareholder VoteJun 13, 20238-KReg FD Disclosure · Company UpdateJun 5, 20238-KCompany UpdateMay 17, 202310-Q10-QMay 5, 20238-KResults of OperationsMay 4, 2023DEFA14AULTRAGENYX PHARMACEUTICAL INC. - DEFA14AApr 24, 2023
Insider Activity
In the 90 days to Mar 10, 2026: 7 sold $2.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sell | 3,508 | $22.67 | $80K |
| Mar 6, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sell | 6,018 | $21.40 | $129K |
| Mar 3, 2026 | Horn HowardChief Financial Officer | Sell | 1,635 | $22.40 | $37K |
| Mar 2, 2026 | Kakkis Emil DPresident & CEO | Sell | 54,404 | $22.80 | $1.2M |
| Mar 2, 2026 | Harris ErikEVP & Chief Commercial Officer | Sell | 10,539 | $22.80 | $240K |
| Mar 2, 2026 | Pinion John RichardSee Remarks | Sell | 10,029 | $22.80 | $229K |
| Mar 2, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sell | 8,135 | $22.80 | $185K |
| Mar 2, 2026 | Crombez EricEVP and Chief Medical Officer | Sell | 7,029 | $22.80 | $160K |
| Mar 2, 2026 | Horn HowardChief Financial Officer | Sell | 5,290 | $22.80 | $121K |
| Mar 2, 2026 | Horn HowardChief Financial Officer | Sell | 3,119 | $22.54 | $70K |
| Mar 2, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sell | 1,632 | $22.80 | $37K |
| Feb 2, 2026 | Horn HowardChief Financial Officer | Sell | 3,061 | $23.56 | $72K |
| Jan 2, 2026 | Horn HowardChief Financial Officer | Sell | 3,150 | $22.84 | $72K |
| Dec 29, 2025 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sell | 85 | $34.38 | $3K |
| Dec 10, 2025 | Horn HowardChief Financial Officer | Sell | 3,081 | $36.38 | $112K |
| Oct 13, 2025 | Horn HowardChief Financial Officer | Sell | 7,942 | $31.51 | $250K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance